Effect and Mechanism of Bifidobacterium animalis B94 in the Prevention and Treatment of Liver Injury in Rats

Tianfang Zhang, Jie Wang, Yao Zhao, Lingmei Ni, Yifan Zhao, Shuang Wei, Zuobing ChenFrontiers in Cellular and Infection Microbiology 2022 · DOI

TL;DR

This study investigates how the probiotic Bifidobacterium animalis B94 protects against and treats liver injury in rats. The findings reveal that B94 improves liver function, reduces intestinal damage, and positively modulates the gut microbiome and its metabolic output, offering a promising therapeutic avenue for liver diseases.

What Problem Does This Paper Address?

Liver failure, a severe condition with high mortality, arises from significant liver damage caused by various factors like viruses, alcohol, and drugs. The liver's essential functions—detoxification, metabolism, and immune defense—are compromised, leading to a cascade of clinical syndromes. While the gut microbiome is increasingly recognized for its role in liver health, with dysbiosis contributing to liver injury, effective interventions are still limited. This paper addresses the need for understanding how probiotics, specifically Bifidobacterium animalis B94, can prevent and treat liver injury by elucidating its underlying mechanisms, particularly its impact on the gut-liver axis.

Methods

The researchers employed a rat model of liver injury induced by D-galactosamine (GalN). They compared three groups: a healthy control (HC), a liver injury group (GalN), and a group treated with Bifidobacterium animalis B94 (B94+GalN).

Key techniques included:

  • Liver Function Assays: Serum markers like ALT, AST, albumin, globulin, and bilirubin were measured using an automated biochemical analyzer to assess liver damage and function.
  • Cytokine Assays: A multiplex assay (Bio-plex Pro) was used to quantify 23 different cytokines in rat serum, focusing on inflammatory markers like MCP-1 and MIP-1α.
  • 16S rRNA Sequencing: Stool samples were analyzed using 16S rRNA sequencing to characterize the gut microbial community composition and diversity (alpha and beta diversity).
  • Faecal Metabolite Analysis: Gas chromatography-mass spectrometry (GC-MS) was used to identify and quantify metabolites in faecal samples, providing insights into the metabolic activity of the gut microbiome.
  • Histopathological Evaluation: Hematoxylin-eosin (HE) staining of intestinal and liver tissues was performed to assess the degree of tissue damage and inflammation.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • B94 as a Protective Agent: B. animalis B94 demonstrated a significant protective effect against D-galactosamine-induced liver injury, not only preventing damage but also aiding in recovery.
  • Gut-Liver Axis Modulation: The study strongly suggests that B94's benefits are mediated through its influence on the gut-liver axis. By improving gut barrier integrity (implied by reduced intestinal damage) and altering the gut microbiome composition and its metabolic output, B94 indirectly supports liver health.
  • Microbiome Rebalancing Act: D-galactosamine induced significant changes in gut microbiota composition, with depletion of beneficial bacteria and enrichment of potentially harmful ones. B94 treatment partially reversed these changes, restoring a more balanced microbial community.
  • Metabolic Footprint of Liver Injury: Liver injury was associated with distinct alterations in faecal metabolites. B94 treatment helped to normalize these metabolic profiles, suggesting a role in restoring metabolic homeostasis.
  • Inflammatory Marker Regulation: B94 was found to attenuate the D-galactosamine-induced increase in pro-inflammatory cytokines like MCP-1 and MIP-1α, indicating an immunomodulatory effect that contributes to liver protection.

Key Results

  • Improved Liver Function: In the B94+GalN group, the albumin/globulin ratio and levels of ALT, AST, TBA, and indirect bilirubin were significantly lower compared to the GalN group. Globulin levels were also improved.
  • Reduced Tissue Damage: Histological examination showed significantly less liver and intestinal tissue damage in the B94+GalN group compared to the GalN group.
  • Microbiota Modulation: While alpha diversity (Shannon and Chao1 indices) was not significantly different, beta diversity analysis (PCoA) showed clear separation of the three groups, indicating distinct microbial community structures. B94 treatment partially reversed the dysbiosis induced by GalN, enriching some beneficial bacteria and depleting others.
  • Metabolome Normalization: OPLS-DA analysis revealed distinct metabolome profiles for each group. B94 treatment mitigated changes in several key metabolites, such as 1-heptadecanol, 5-aminovaleric acid, and N-acetyl glucosamine, which were altered by GalN.
  • Cytokine Regulation: B94 administration attenuated the D-galactosamine-induced elevation of MCP-1 and MIP-1α in serum.

Limitations and Future Work

  • Animal Model: The study was conducted in a rat model. While informative, further clinical validation in humans is necessary to confirm these findings and assess the therapeutic potential of B94 for liver injury and failure.
  • Mechanistic Depth: While the study identifies key changes in the microbiome and metabolome, the precise molecular mechanisms by which B94 exerts its effects require further in-depth investigation.
  • Specific Bacterial Roles: The study identified specific bacterial taxa that were altered by B94. Future research could focus on the specific roles of these individual bacteria and their metabolites in the context of liver protection.
  • Long-term Effects: The study focused on the immediate effects of B94 treatment. Investigating the long-term efficacy and safety of B94 in preventing or treating chronic liver conditions would be valuable.

Summary updated

Abstract

<i>Bifidobacterium animalis</i> B94 can affect the process of liver injury in rats by improving liver function, reducing intestinal damage, and regulating gut microbiota and metabolite production.
BibTeX
@inproceedings{zhang2022effect,
  author = {Tianfang Zhang and Jie Wang and Yao Zhao and Lingmei Ni and Yifan Zhao and Shuang Wei and Zuobing Chen},
  title = {{Effect and Mechanism of Bifidobacterium animalis B94 in the Prevention and Treatment of Liver Injury in Rats}},
  booktitle = {Frontiers in Cellular and Infection Microbiology},
  year = {2022},
  doi = {10.3389/fcimb.2022.914684},
}
Figure